Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprexa IM "Approvable"; GMP Consultants Hired In Wake Of Inspections

Executive Summary

Lilly believes Zyprexa IM is on track for a late summer launch following receipt of an "approvable" letter from FDA.

You may also be interested in...



FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

Lilly Symbyax Combo Clears FDA; Price, Dose Will Help Distinguish Brand

Lilly's launch plans for the bipolar depression therapy Symbyax combine a value pricing model with a unique dosing combination

Related Content

UsernamePublicRestriction

Register

PS037664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel